Doxa AB (DOXA) AI Stock Analysis

• Market Cap: kr639.55M
• Dividend Yield: N/A
• Average Volume (3M): 871.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: 3.57%
• EPS Growth: -925.35%
• Country: SE
• Employees: 5
• Sector: Real Estate
• Sector Strength: 53
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.10
• Shares Outstanding: 1,285,530,600
• 10 Day Avg. Volume: 864,869
• 30 Day Avg. Volume: 871,447
• PEG Ratio: <0.01
• Price to Book (P/B): 0.24
• Price to Sales (P/S): 36.41
• P/FCF Ratio: -8.87
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr0.55
• Price Target Upside: 9.69% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 47 Neutral
• Price Target: kr0.50 ▲(0.00% Upside)

Doxa AB's overall stock score is primarily impacted by its weak financial performance, characterized by negative profitability and rising debt levels. Technical analysis provides a slightly more positive outlook, but valuation concerns due to a negative P/E ratio and lack of dividend yield further weigh down the score.

Doxa AB Business Overview & Revenue Model

Company Description

Doxa AB (publ), a dental company, develops, manufactures, and commercializes bioceramic dental products under the Ceramir brand worldwide. It offers Crown & Bridge, a dental cement that is used for permanent cementing of crowns and bridges. The company was founded in 1987 and is based in Uppsala, Sweden.

How the Company Makes Money

Doxa AB generates revenue through the sale of its dental products, particularly the Ceramir range of dental cements. The company markets its products to dental professionals and clinics, leveraging a network of distributors to reach a global market. In addition to direct sales, Doxa may engage in partnerships with dental product distributors and manufacturers, enhancing its market reach and distribution capabilities. The company's earnings are influenced by its ability to innovate and meet the evolving needs of the dental industry, as well as its strategic relationships with key industry players.

Doxa AB Financial Statement Overview

Summary

Doxa AB is facing financial difficulties across all major statements. Negative margins and profitability, coupled with rising debt levels and weak cash flow generation, present significant risks. The company must address its cash management and cost structure to ensure financial sustainability. While equity remains a strong point, leveraging and liquidity challenges overshadow it.

Income Statement

Doxa AB's income statement highlights significant challenges, with consistent negative net income and declining EBIT over the years. The company has not been able to maintain profitability, evidenced by negative EBIT and EBITDA margins, especially in the TTM period. Revenue growth is volatile, with recent declines indicating further instability in financial performance.

Balance Sheet

While Doxa AB has a relatively high level of stockholders' equity compared to its total assets, indicating a strong equity ratio, the increasing level of debt over recent periods raises leverage concerns. The debt-to-equity ratio has worsened, suggesting higher financial risk. Stability is mitigated by significant liabilities and declining asset values.

Cash Flow

The cash flow statement reveals persistent negative operating cash flows and free cash flows, indicating cash management issues. The free cash flow growth rate is negative, showing a lack of improvement in cash flow generation. Additionally, the operating cash flow to net income ratio indicates inefficiency in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.40M	15.50M	9.90M	5.20M	10.90M	8.54M
Gross Profit	4.90M	15.50M	9.90M	5.20M	7.90M	8.40M
EBITDA	-858.35M	-1.70B	296.00M	-39.80M	77.20M	-12.20M
Net Income	-1.42B	-1.72B	291.90M	-39.90M	76.20M	-13.69M
Balance Sheet
Total Assets	4.51B	8.20B	3.50B	1.79B	878.80M	14.48M
Cash, Cash Equivalents and Short-Term Investments	61.50M	70.60M	111.90M	60.00M	15.10M	4.58M
Total Debt	1.66B	3.63B	256.50M	4.90M	0.00	0.00
Total Liabilities	2.37B	5.89B	280.80M	18.30M	9.00M	5.04M
Stockholders Equity	2.15B	2.31B	3.22B	1.77B	869.80M	9.44M
Cash Flow
Free Cash Flow	-437.90M	-63.60M	-37.80M	-39.40M	-18.60M	-15.66M
Operating Cash Flow	-437.90M	-63.20M	-37.80M	-38.50M	-18.60M	-14.28M
Investing Cash Flow	123.80M	-834.90M	-205.10M	-267.30M	-392.90M	-1.34M
Financing Cash Flow	364.20M	807.70M	294.70M	350.70M	422.10M	14.60M

Doxa AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.50
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:DOXA, the sentiment is Negative. The current price of 0.5 is below the 20-day moving average (MA) of 0.53, below the 50-day MA of 0.52, and above the 200-day MA of 0.45, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.38 is Neutral, neither overbought nor oversold. The STOCH value of 40.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:DOXA.

Doxa AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	$2.17B	12.19	3.79%	4.94%	3.15%	1.96%
S2M	61 Neutral	€10.30M	―	―	―	―	―
FLUO	48 Neutral	kr582.94M	―	―	―	―	23.67%
DOXA	47 Neutral	kr639.55M	―	-51.41%	―	3.57%	-925.35%
LCLEAN	45 Neutral	kr45.64M	―	-598.14%	―	-3.09%	29.52%
IZAFE.B	45 Neutral	€252.73M	―	-123.69%	―	43.22%	47.78%
QLINEA	41 Neutral	€173.48M	―	-330.10%	―	16.98%	50.52%